Zirkulierende Tumor-DNA — minimale Resterkrankung (ctDNA-MRD)
Deterministische Ansicht der Quelle YAML Entität. Klinische Autorität bleibt mit den zitierten Quell-IDs und Rezensenten Sign-off Zustand.
| ID | BIO-CTDNA-MRD |
|---|---|
| Art | Biomarker |
| Aliase | MRD durch flüssige Biopsiezirkulierende Tumor DNA MRDktDNA MRDktDNA-MRDmolekulare RestkrankheitЦиркулююча пухлинна ДНК — мінімальна залишкова хвороба (цтДНК-МЗХ) |
| Status | reviewed 2026-04-29 | pending_clinical_signoff |
| Erkrankungen | None declared |
| Quellen | SRC-CIVIC SRC-ESMO-CRC-2024 SRC-NCCN-COLON-2025 |
Biomarker-Fakten
| Biomarker-Typ | composite_score |
|---|---|
| Messung | VerfahrenFlüssige Biopsie (peripheres Blutplasma): Tumor-informierter Assay (z.B. Signatera-gesprochenes Panel aus primärem Tumor WES) ODER tumor-agnostisches Panel; quantitativer VAF oder qualitativer positiver/negativer Anruf Einheitencategorical (positive | negative) and/or continuous (mean tumor molecules per mL plasma, MTM/mL) |
| Verwandte Biomarker | None declared |
Anmerkungen
Lineage-agnostic post-treatment surveillance / risk-stratification biomarker. Two assay families: - **Tumor-informed (bespoke):** Signatera (Natera), RaDaR (NeoGenomics / Inivata) — primary tumor WES designs a patient-specific multi-locus panel; high analytic sensitivity (~0.01% VAF). - **Tumor-agnostic:** fixed-panel ctDNA assays — broader coverage of recurrent driver mutations / methylation signatures; lower specificity for low tumor burden. **CRC adjuvant (strongest evidence base):** - **GALAXY (CIRCULATE-Japan, Kotani et al. Nat Med 2023):** Stage II-IV CRC, post-curative resection, Signatera. Post-op MRD-positive patients had ~22% 18-month DFS vs ~93% MRD-negative. MRD-positive benefited substantially from adjuvant chemotherapy (vs no benefit or marginal benefit in MRD-negative). Established ctDNA-MRD as a clinically actionable risk stratifier in CRC. - **CIRCULATE-Japan ALTAIR / VEGA / CIRCULATE-US:** ongoing randomized trials of MRD-driven escalation/de-escalation. **Other lineages with growing evidence:** - Muscle-invasive bladder cancer (IMvigor010 ctDNA subgroup): MRD+ benefited from adjuvant atezolizumab; MRD- did not. - Breast (early HR+/HER2+): emerging from c-TRAK-TN...
Verwendet von
Biomarker
BIO-CEA-CRC-MONITORING- CEA (Karzinoembryonalantigen) — CRC-Überwachung nach der BehandlungBIO-CTDNA-MRD-POST-TREATMENT- ctDNA-basierte minimale Resterkrankung (MRD) — Überwachung nach der Behandlung